A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL)

Beltrán B.E.; Villela L.; Torres M.A.; Otero V.; Fiad L.; Peña C.; Cabrera M.E.; León P.; Idrobo H.; Castro D.A.; Paredes S.; Perdomo I.; Abello V.; Rojas C.; Ramirez-Ibargüen A.; Candelaria M.; Pérez-Jacobo F.; Montaño-Figueroa E.; Best C.; Goméz-De Leon A.; Gómez-Almaguer D.; Ruiz-Argüelles G.; Hernández-Hernández J.; Malpica L.; Sotomayor E.M.; Castillo J.J. · Clinical Lymphoma, Myeloma and Leukemia (2020) · DOI: 10.1016/j.clml.2020.04.016

Resumen

Introduction: We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy. Patients and Methods: The learning cohort was composed of 274 patients and the validation cohort of 323 patients, for a total of 597 patients. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis. Results: In multivariate models, NLR ≥ 4 was independently associated with lower odds for complete response to chemoimmunotherapy in the learning (odds ratio, 0.46; P =.006) and the validation cohort (odds ratio, 0.49; P =.01), and independently associated with worse survival in the learning (hazard ratio, 1.55; P =.04) and the validation cohort (hazard ratio, 1.80; P =.003). Conclusions: The adverse prognostic value of NLR ≥ 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score. Based on the results of this multi-institutional study, NLR ≥ 4 emerges as an adverse prognostic factor in Latin American patients with DLBCL treated with chemoimmunotherapy.

Instituciones: Universidad de San Martín de Porres